Acne Claims For Cosmetics Leave Blemish On UK Advertising Regs
This article was originally published in The Pink Sheet & The Rose Sheet
Advertising Standards Authority issued decisions Oct. 17 on complaints against three cosmetics brands and an online beauty retailer for statements the independent regulator reads as acne-treatment claims, or the “spots” equivalent, calling them medicinal claims for unlicensed products.
You may also be interested in...
FDA’s warning letter to Skin 2 Sprit prompts a quick fix of website claims for the company’s skin care products. FDA advises Moon Valley Natural Products to correct claims that quality its skin care products as misbranded drugs.
Galderma Labs' adapalene gel is pending launch as first OTC acne ingredient approved through an NDA and first new acne ingredient available OTC in 20 years, but company must play in a digitally-oriented marketplace.
Bundled within the draft FDA Safety and Landmark Enhancements Act are federal cosmetics reform provisions that would require facility registration and product listings with the US FDA, adverse event reporting and good manufacturing practices, while empowering the agency to order product recalls, access company records, and suspend dangerous operations.